Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 12Gemcitabine 9Specimen Handling 6Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Drug Therapy 5toripalimab 4Platinum 4Nivolumab 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3Radiotherapy 3Immune Checkpoint Inhibitors 3sintilimab 2Ipilimumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2tislelizumab 1relatlimab 1pembrolizumab 1olaparib 1fluciclovine F-18 1dehydroftorafur 1cemiplimab 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × 18-O-demethylcervinomycin A2 × 30 days × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡